Ultragenyx sells $500M in royalty interest on rare disease drug to Canadian pension plan
Ultragenyx said early Thursday it has sold 30% of its royalty interest from Kyowa Kirin on future sales of the companies’ rare disease drug Crysvita …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.